Quote | NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO)
Last: | $4.4702 |
---|---|
Change Percent: | 1.71% |
Open: | $4.6 |
Close: | $4.4702 |
High: | $4.8 |
Low: | $4.4702 |
Volume: | 33,590 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO)
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...
Message Board Posts | NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO)
Subject | By | Source | When |
---|---|---|---|
here we go bulls news is here | db101 | investorshub | 01/31/2024 11:30:13 PM |
Price now last up | SmellMyFinger | investorshub | 01/31/2024 11:04:25 PM |
$NRBO short squeeze signal | reena969 | investorshub | 01/31/2024 7:51:08 PM |
Thoughts on where this is headed? | tw0122 | investorshub | 01/31/2024 3:47:01 PM |
The now | PennyPusher786 | investorshub | 01/31/2024 10:22:13 AM |
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in...